Encouraging Trends in Modern Phase 1 Oncology Trials

Historically, phase 1 trials have been aimed at defining the toxic effects of an agent. With the advent of targeted therapies and immunotherapies, response rates in 224 phase 1 trials reported from January 1, 2014, through June 30, 2015, were nearly 20%.

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 378; no. 23; pp. 2242 - 2243
Main Authors:	Chakiba, Camille, Grellety, Thomas, Bellera, Carine, Italiano, Antoine
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 07-06-2018
Subjects:	Clinical Trials, Phase I as Topic Humans Neoplasms - drug therapy Research Support as Topic Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Historically, phase 1 trials have been aimed at defining the toxic effects of an agent. With the advent of targeted therapies and immunotherapies, response rates in 224 phase 1 trials reported from January 1, 2014, through June 30, 2015, were nearly 20%.
Bibliography:	SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc1803837